Articles tagged with Crohn Disease
A new study found that children diagnosed with IBD before the age of six show biological changes associated with the disease at birth. This suggests that these children are part of a severely affected subgroup, making preventive options crucial for their investigation. The study's findings could lead to earlier screening and potentiall...
Researchers at TUM found that mitochondrial dysfunction in mice leads to chronic intestinal inflammation and changes in the gut microbiome. The study suggests potential new treatments targeting mitochondrial pathways or addressing the connections between the microbiome and mitochondria.
A recent survey by the Crohn's & Colitis Foundation found that over 40% of IBD patients have made substantial financial trade-offs to access their care. Among these respondents, 22% increased their credit card debt, while 21% cut back on essential items like food and clothing.
Researchers at University of California - San Diego have discovered that Crohn's disease consists of two distinct molecular subtypes, each exhibiting unique patterns of genetic mutation and cellular phenotypes. This finding could lead to more effective management strategies, with therapies tailored to specific subtypes.
Associate Professor Justine Tigno-Aranjuez received a $1 million NSF CAREER Award to study the impact of the NOD2 pathway on inflammation. Her research aims to understand how lipid mediators are produced and how they influence inflammation.
Established biomarkers such as CRP, ESR, vitamin D, and platelets continue to be vital in IBD management. Novel biomarkers like MAdCAM-1, oncostatin M, NOD2 mutations, and anti-Integrin αvβ6 offer promise for improving diagnostic accuracy and predicting treatment response.
A new study published in Science Advances has found that antibiotics disrupt the protective mucus layer in the intestine, increasing the risk of inflammatory bowel disease. Researchers discovered that antibiotics damage the mucus barrier in a microbiota-independent manner, facilitating bacterial penetration and gut inflammation.
Researchers explore fecal calprotectin and C-reactive protein as biomarkers for inflammatory bowel diseases (IBD), with multi-target tools showing promising results. These biomarkers hold potential for improving diagnostic accuracy and monitoring disease activity, leading to more effective IBD management.
A newly developed granzyme B PET imaging method can non-invasively detect IBD and provide a real-time picture of active inflammation. This technology could guide personalized patient management strategies and monitor treatment efficacy.
Research by a University of Virginia undergraduate may help explain recurrent Crohn’s disease in children and open the door to new ways to treat or even cure the devastating condition. Children with relapsing Crohn’s had persistent disruptions of their microbiomes even after inflammation was successfully controlled.
Researchers have successfully grown 'mini-guts' in the lab to better understand Crohn's disease. The organoids show that epigenetic changes play an important role in the disease and its severity, enabling potential personalized treatments. This breakthrough could lead to more precise and effective treatments for patients.
A groundbreaking IBD study aims to identify biomarkers for personalized treatment, monitoring, and prediction. Researchers will collect genomic data from 1,000 newly diagnosed patients in the UK over four years.
A study by Mount Sinai researchers has identified several pathophysiological mechanisms underlying perianal fistulae in Crohn’s disease. The findings highlight key transcription factor binding events and epigenetic phenomena that contribute to the higher rates of complications in African American patients. The research provides avenues...
Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.
Researchers discovered that gut bacteria can dynamically reprogram gene expression based on local conditions like inflammation or viral attacks. This adaptation strategy may worsen disease by crippling production of molecules that regulate the immune system and attenuate gut inflammation.
A new testing protocol combining clinical history with multiple home stool tests could significantly speed up diagnosis of inflammatory bowel disease (IBD) by reducing the need for unnecessary colonoscopies. Serial faecal calprotectin tests were found to strongly predict possible IBD, Crohn's Disease, and Ulcerative Colitis.
Researchers found a link between low fiber diets, mucin-degrading bacteria, and increased inflammation in mice with IBD genetics. A high-fiber diet prevented inflammation and even reversed symptoms in some cases.
A Northwestern University team developed a wireless, implantable temperature sensor to monitor inflammatory flareups in patients with Crohn's disease. This allows clinicians to act earlier to prevent permanent damage caused by inflammatory episodes.
Researchers discover that certain bacteria can evade the immune system by circumventing antibody coating, leading to severe inflammation. The study identifies IgG2 as a key player in this process, providing potential biomarkers and targets for new treatments.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
A large-scale clinical trial has shown that offering early advanced therapy to newly-diagnosed Crohn's patients can drastically improve outcomes, including reducing the need for urgent abdominal surgery. The 'top-down' treatment strategy, which involves providing infliximab as soon as possible after diagnosis, resulted in significantly...
A study of over 80,000 children found that high fish and vegetable intakes early in life are associated with a lower risk of inflammatory bowel disease. High sugar beverage intake, on the other hand, was linked to a higher risk.
The Icahn School of Medicine at Mount Sinai will investigate the pre-disease phase of Crohn's disease, identifying unique biomarkers to predict and prevent its development. The $4 million grant aims to transform healthcare by focusing on early intervention and prevention strategies.
Researchers from Scripps Research have developed a small molecule that blocks the activity of SLC15A4, a protein linked to autoimmune diseases like lupus and Crohn's disease. The compound, FFF-21, successfully reduced inflammation in mouse models and isolated cells from people with lupus.
A new consortium, co-led by Florian Rieder, MD, and Vipul Jairath, MD, will create clinical care pathways toward drug development and improve disease management for patients with Crohn's disease and permanent ileostomy. The EndO-trial Consortium aims to develop effective drugs and measure treatment outcomes using patient-reported outco...
Researchers found IBD manifests differently among various racial groups and immigration statuses. Genetic and environmental factors contribute to varying disease courses and symptoms.
The AGA releases its first comprehensive evidence-based guideline for managing pouchitis, a complication of ulcerative colitis surgery. The guideline recommends treatment with antibiotics and multi-strain probiotics to prevent recurrent pouchitis.
A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.
Scientists at University of California San Diego develop a new approach to microbiome research, identifying hundreds of molecules never seen before in the human body. They found a strong association between these molecules and inflammatory bowel disease, potentially leading to new diagnostic and therapeutic applications.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
The American Gastroenterological Association released a new guideline recommending the use of biomarkers to help manage Crohn’s disease. Biomarkers such as C-reactive protein and fecal calprotectin can measure levels of inflammation, helping doctors assess disease activity and guide treatment decisions.
Researchers found that rare gene variants associated with inflammatory bowel disease (IBD) are less prevalent in African Americans, suggesting a different genetic contribution to the disease. The study highlights the importance of considering genetic diversity and admixture in IBD research.
A study published in mSystems found that mice fed a broccoli sprout diet had milder disease symptoms and richer gut microbial communities compared to those not exposed. The researchers suggest that broccoli sprouts could be used as a treatment strategy for patients with IBD.
Researchers discovered subtle changes in minerals, cells, and inflammation markers in people with inflammatory bowel disease up to 8 years before diagnosis. These findings suggest an opportunity for preventative action or early treatment to improve quality of life.
Research at the University of Gothenburg found that even low-active IBD patients have a higher risk of serious infections due to microscopic intestinal inflammation. Achieving a fully healed intestinal mucosa may reduce this risk, contributing to lower morbidity and mortality in IBD patients.
A new study from the University of Pennsylvania School of Medicine found a significant link between inflammatory bowel disease (IBD) and atopic dermatitis (AD), with adults having a 34% increased risk and children having a 44% increased risk. The severity of AD was also associated with an increased risk of developing IBD.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
Researchers have developed a less invasive test for inflammatory bowel disease by analyzing the sugar molecules attached to antibodies. The study found distinct patterns of glycans on immunoglobulin A (IgA) antibodies between patients with Crohn's disease and ulcerative colitis, which could lead to a simple blood-based diagnostic test.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
Researchers at Karolinska Institutet found that statin treatment was associated with a lower risk of developing and dying from colorectal cancer in patients with ulcerative colitis. After a follow-up period of 5.6 years, the study showed that 70 statin users had been diagnosed with colorectal cancer compared to 90 non-statin users.
A radiomic-based model using T2-weighted MRI data achieved high accuracy in diagnosing pediatric Crohn disease, outperforming expert radiologists. The model was ensembled with clinical data to further improve performance.
Researchers developed nanoparticles that mimic the glycocalyx pattern to treat inflammatory bowel disease. The treatment reduced symptoms and inflammation in mice with IBD, with specific versions showing significant improvement.
Researchers have developed a microgel delivery system that keeps beneficial bacteria safe while actively clearing out harmful ones in the gut. In mice, this system treated intestinal inflammation without side effects and showed promise as a viable treatment strategy for intestinal diseases.
Research by West Virginia University professor Sean Tu found that orphan drugs earn pharmaceutical companies almost as much as those marketed to the general public. The Orphan Drug Act incentivizes companies with tax credits, longer patent exclusivity, and easier FDA review for treating rare diseases.
A new study suggests that high-sugar diets can exacerbate inflammatory bowel disease (IBD) symptoms by disrupting the colon's lining renewal process. The research found that a high-sugar diet led to impaired cell division and altered metabolic pathways in mice, resulting in faster gut damage.
Researchers developed human calprotectin ligands based on peptides to detect and quantify the protein in stool samples or serum levels, offering a more accurate and controlled way of detecting biomarkers.
Researchers at MIT have designed new 'smart' sutures that can deliver drugs or sense inflammation after surgery. The bioderived sutures use hydrogel coatings to detect early warning signs of complications, such as Crohn's disease, and can also release therapeutic molecules to promote healing.
A study published in Cell Reports Medicine found that pro-inflammatory cell types dominate the intestinal mucosa of children with inflammatory bowel disease, while protective cells are underrepresented. The results provide new insights into the immunology of IBD and may lead to the development of more effective treatments.
A study published in Microorganisms shows that melatonin can aggravate Crohn's disease and ulcerative colitis by disrupting the balance of gut microbiota. The hormone, commonly used to improve sleep, had negative effects on bowel inflammation in laboratory mice, depending on their microbiota profile.
A new study by UCL researchers hints at the possibility of detecting conditions such as coeliac disease and Parkinson's disease in principle up to 10 years before diagnosis. The review of existing evidence indicates a 'diagnostic window' – the point at which diagnosis may be possible for some patients.
A new Cochrane Review found that stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection by 77%, compared to 40% with standard antibiotic treatment. The study also showed a decrease in side effects with stool transplantation.
Researchers at Cedars-Sinai Medical Center identified a genetic variant associated with increased risk of developing perianal Crohn's disease, a debilitating manifestation of Crohn's disease. The study highlights the importance of targeting the alternative complement pathway and Complement Factor B (CFB) in treating this condition.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
A UC Riverside-led study found that reduced PTPN2 activity in intestinal epithelial cells leads to decreased Paneth cell antimicrobial peptide production, disrupting the gut microbiota and increasing E. coli. This loss can serve as a marker of IBD disease.
A new imaging technique using a novel nuclear medicine tracer has been developed to improve the treatment of intestinal strictures in Crohn's disease patients. The technique allows for precise differentiation between inflammation and fibrosis, enabling targeted therapy.
Researchers from the University of North Carolina Health Care announce that patients receiving anti-TNF biologic treatments combined with methotrexate had better outcomes than those treated with adalimumab alone. The study, published in Gastroenterology, provides clear results that can immediately impact patient care.
Researchers found that a combination of IL-22 and IL-1R inhibitors could be a promising treatment for inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The study suggests that targeting both pathways may lead to more effective treatment outcomes.
Researchers at Mayo Clinic found that a dissolvable plug delivering stem cells can heal single-tract fistulas in patients with Crohn's disease. The treatment has shown durable results with minimal side effects, offering hope for patients with refractory perianal fistulas.
Researchers at Karolinska Institutet have developed a new approach to treating inflammatory diseases by analyzing the activity of genes in individual cells. This digital twin technology could lead to personalized drug therapies for patients with conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
A new study found that individuals with a normal gastrointestinal biopsy still have a higher risk of developing inflammatory bowel disease (IBD) in the years following the biopsy. The study of over 450,000 individuals in Sweden showed that symptoms of IBD may start significantly before the disease shows up on biopsy.